

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:

GOLDENBERG

Application No.: 10/672,278

Filed: 9/29/2003

For: CHIMERIC, HUMAN AND
HUMANIZED ANTI-GRANULOCYTE
ANTIBODIES AND METHOD OF USE

Examiner:

Art Unit: 1645

INFORMATION DISCLOSURE STATEMENT
(37 C.F.R. §§ 1.97(b)(3) and 1.98)

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Sir:

The Examiner is requested to consider the references noted on the enclosed Form PTO/SB/08A (Substitute for form 1449A/PTO) during examination of the above-identified application. These references are submitted for the Examiner's consideration and are submitted pursuant to the duty of disclosure under 37 C.F.R. § 1.56. In submitting these references, no representation is made or implied that the references are or are not material to the examination of the application. The Examiner is encouraged to make his or her own determination of materiality.

The fee set forth in 37 CFR 1.17(p) has been submitted herewith. Should any additional fees and/or any underpayment of fee(s); credit any overpayments be deemed necessary, such fees may be charged to Deposit Account No. 06-0029.

Should the examiner have any questions concerning the relevance of any reference cited in this disclosure, please contact the undersigned attorney.

Dated: November 17, 2006

Respectfully submitted,

A handwritten signature in black ink, appearing to read 'Richard A. Nakashima', is written over a horizontal line.

Richard A. Nakashima
Registration No. 42,023
Customer No. 35657